The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | What we still don’t know about the RATIFY study of midostaurin in AML
The Phase III RATIFY study (NCT00651261) investigated daunorubicin, cytarabine and the FLT3 inhibitor midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Here, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the questions remaining from this trial, speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
